Anti-adalimumab antibodies in a cohort of patients with juvenile idiopathic arthritis

incidence and clinical correlations

Achille Marino, Feliciana Real-Fernández, Paolo Rovero, Teresa Giani, Ilaria Pagnini, Rolando Cimaz, Gabriele Simonini

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Adalimumab is a TNF-α blocker antibody similar in structure and function to natural human IgG1. Even if adalimumab is fully humanized, the development of anti-drug antibodies has been reported in several inflammatory conditions. The objective of our study was to assess the presence of anti-adalimumab antibodies (AAA) and their clinical relevance in a cohort of juvenile idiopathic arthritis (JIA) patients on adalimumab. This is a prospective observational cohort study recruiting JIA children. Experiments were performed using a validated surface plasmon resonance (SPR)-based optical assay (Biacore® T100). Disease activity was evaluated using the Juvenile Arthritis Disease Activity Score with 10 joint count (JADAS-10). The Mann-Whitney U test, Wilcoxon signed-rank test for paired samples, chi-square, and Fisher exact test were used to compare data. Pearson's and Spearman's correlation tests were used to determine correlation coefficients for entered variables: demographic, clinical, and serological data. Ten (37%) out of 27 patients included in the study had at least one AAA-positive sample. Patients developed AAA between 3 and 38 months after starting adalimumab. Seven (70%) out of 10 children with AAA positivity experienced at least a relapse compared to 4 (23.5%) out of 17 AAA-negative children (rs0.45, p < 0.017). In conclusion, using an innovative and accurate assay method, we found a high incidence of anti-drug antibodies in a cohort of adalimumab-treated JIA patients observed over a mean period of 40 weeks; the presence of anti-adalimumab antibodies seemed to be related to the number of relapses.

Original languageEnglish
Pages (from-to)1407-1411
Number of pages5
JournalClinical Rheumatology
Volume37
Issue number5
Early online date5 Mar 2018
DOIs
Publication statusPublished - May 2018

Fingerprint

Juvenile Arthritis
Anti-Idiotypic Antibodies
Incidence
Nonparametric Statistics
Adalimumab
Recurrence
Surface Plasmon Resonance
Pharmaceutical Preparations
Observational Studies
Cohort Studies
Immunoglobulin G
Joints
Demography

Keywords

  • Journal Article
  • Adalimumab
  • Immunogenicity
  • JIA
  • Surface plasmon resonance

Cite this

Anti-adalimumab antibodies in a cohort of patients with juvenile idiopathic arthritis : incidence and clinical correlations. / Marino, Achille; Real-Fernández, Feliciana; Rovero, Paolo; Giani, Teresa; Pagnini, Ilaria; Cimaz, Rolando; Simonini, Gabriele.

In: Clinical Rheumatology, Vol. 37, No. 5, 05.2018, p. 1407-1411.

Research output: Contribution to journalArticle

Marino, Achille ; Real-Fernández, Feliciana ; Rovero, Paolo ; Giani, Teresa ; Pagnini, Ilaria ; Cimaz, Rolando ; Simonini, Gabriele. / Anti-adalimumab antibodies in a cohort of patients with juvenile idiopathic arthritis : incidence and clinical correlations. In: Clinical Rheumatology. 2018 ; Vol. 37, No. 5. pp. 1407-1411.
@article{1fce465d34074a7b94987aad91b958c9,
title = "Anti-adalimumab antibodies in a cohort of patients with juvenile idiopathic arthritis: incidence and clinical correlations",
abstract = "Adalimumab is a TNF-α blocker antibody similar in structure and function to natural human IgG1. Even if adalimumab is fully humanized, the development of anti-drug antibodies has been reported in several inflammatory conditions. The objective of our study was to assess the presence of anti-adalimumab antibodies (AAA) and their clinical relevance in a cohort of juvenile idiopathic arthritis (JIA) patients on adalimumab. This is a prospective observational cohort study recruiting JIA children. Experiments were performed using a validated surface plasmon resonance (SPR)-based optical assay (Biacore{\circledR} T100). Disease activity was evaluated using the Juvenile Arthritis Disease Activity Score with 10 joint count (JADAS-10). The Mann-Whitney U test, Wilcoxon signed-rank test for paired samples, chi-square, and Fisher exact test were used to compare data. Pearson's and Spearman's correlation tests were used to determine correlation coefficients for entered variables: demographic, clinical, and serological data. Ten (37{\%}) out of 27 patients included in the study had at least one AAA-positive sample. Patients developed AAA between 3 and 38 months after starting adalimumab. Seven (70{\%}) out of 10 children with AAA positivity experienced at least a relapse compared to 4 (23.5{\%}) out of 17 AAA-negative children (rs0.45, p < 0.017). In conclusion, using an innovative and accurate assay method, we found a high incidence of anti-drug antibodies in a cohort of adalimumab-treated JIA patients observed over a mean period of 40 weeks; the presence of anti-adalimumab antibodies seemed to be related to the number of relapses.",
keywords = "Journal Article, Adalimumab , Immunogenicity , JIA, Surface plasmon resonance",
author = "Achille Marino and Feliciana Real-Fern{\'a}ndez and Paolo Rovero and Teresa Giani and Ilaria Pagnini and Rolando Cimaz and Gabriele Simonini",
year = "2018",
month = "5",
doi = "10.1007/s10067-018-4057-7",
language = "English",
volume = "37",
pages = "1407--1411",
journal = "Clinical Rheumatology",
issn = "0770-3198",
publisher = "Springer London",
number = "5",

}

TY - JOUR

T1 - Anti-adalimumab antibodies in a cohort of patients with juvenile idiopathic arthritis

T2 - incidence and clinical correlations

AU - Marino, Achille

AU - Real-Fernández, Feliciana

AU - Rovero, Paolo

AU - Giani, Teresa

AU - Pagnini, Ilaria

AU - Cimaz, Rolando

AU - Simonini, Gabriele

PY - 2018/5

Y1 - 2018/5

N2 - Adalimumab is a TNF-α blocker antibody similar in structure and function to natural human IgG1. Even if adalimumab is fully humanized, the development of anti-drug antibodies has been reported in several inflammatory conditions. The objective of our study was to assess the presence of anti-adalimumab antibodies (AAA) and their clinical relevance in a cohort of juvenile idiopathic arthritis (JIA) patients on adalimumab. This is a prospective observational cohort study recruiting JIA children. Experiments were performed using a validated surface plasmon resonance (SPR)-based optical assay (Biacore® T100). Disease activity was evaluated using the Juvenile Arthritis Disease Activity Score with 10 joint count (JADAS-10). The Mann-Whitney U test, Wilcoxon signed-rank test for paired samples, chi-square, and Fisher exact test were used to compare data. Pearson's and Spearman's correlation tests were used to determine correlation coefficients for entered variables: demographic, clinical, and serological data. Ten (37%) out of 27 patients included in the study had at least one AAA-positive sample. Patients developed AAA between 3 and 38 months after starting adalimumab. Seven (70%) out of 10 children with AAA positivity experienced at least a relapse compared to 4 (23.5%) out of 17 AAA-negative children (rs0.45, p < 0.017). In conclusion, using an innovative and accurate assay method, we found a high incidence of anti-drug antibodies in a cohort of adalimumab-treated JIA patients observed over a mean period of 40 weeks; the presence of anti-adalimumab antibodies seemed to be related to the number of relapses.

AB - Adalimumab is a TNF-α blocker antibody similar in structure and function to natural human IgG1. Even if adalimumab is fully humanized, the development of anti-drug antibodies has been reported in several inflammatory conditions. The objective of our study was to assess the presence of anti-adalimumab antibodies (AAA) and their clinical relevance in a cohort of juvenile idiopathic arthritis (JIA) patients on adalimumab. This is a prospective observational cohort study recruiting JIA children. Experiments were performed using a validated surface plasmon resonance (SPR)-based optical assay (Biacore® T100). Disease activity was evaluated using the Juvenile Arthritis Disease Activity Score with 10 joint count (JADAS-10). The Mann-Whitney U test, Wilcoxon signed-rank test for paired samples, chi-square, and Fisher exact test were used to compare data. Pearson's and Spearman's correlation tests were used to determine correlation coefficients for entered variables: demographic, clinical, and serological data. Ten (37%) out of 27 patients included in the study had at least one AAA-positive sample. Patients developed AAA between 3 and 38 months after starting adalimumab. Seven (70%) out of 10 children with AAA positivity experienced at least a relapse compared to 4 (23.5%) out of 17 AAA-negative children (rs0.45, p < 0.017). In conclusion, using an innovative and accurate assay method, we found a high incidence of anti-drug antibodies in a cohort of adalimumab-treated JIA patients observed over a mean period of 40 weeks; the presence of anti-adalimumab antibodies seemed to be related to the number of relapses.

KW - Journal Article

KW - Adalimumab

KW - Immunogenicity

KW - JIA

KW - Surface plasmon resonance

U2 - 10.1007/s10067-018-4057-7

DO - 10.1007/s10067-018-4057-7

M3 - Article

VL - 37

SP - 1407

EP - 1411

JO - Clinical Rheumatology

JF - Clinical Rheumatology

SN - 0770-3198

IS - 5

ER -